To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Bill: 117-hr-6832
Sponsor: full_name: Rep. Cloud, Michael [R-TX-27]
Introduced: 2022-02-25
Policy area: Health
Subjects: Cardiovascular and respiratory health

Drug safety, medical device, and laboratory regulation

Drug therapy

Emergency medical services and trauma care

Health care coverage and access

Health programs administration and funding

Health technology, devices, supplies

Infectious and parasitic diseases

Intergovernmental relations

Military procurement, research, weapons development

Presidents and presidential powers, Vice Presidents

Public contracts and procurement

State and local government operations
Latest action: action_date: 2022-02-28
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-02-25
action_desc: Introduced in House
text: <p>This bill restricts various presidential and federal authorities related to the acquisition of supplies to combat COVID-19.</p> <p>Specifically, the bill prohibits the President from exercising certain authorities under the Defense Production Act of 1950 to prioritize the performance of federal contracts or orders for COVID-19 supplies over the performance of state or territorial contracts or orders. In addition, states or territories may use federal COVID-19 relief funds for COVID-19 supplies that they had been unable to purchase because of prioritized performance of federal contracts or orders. (The Defense Production Act of 1950 confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense.)</p> <p>Additionally, the Food and Drug Administration may not ration, limit, restrict access to, or otherwise control the quantity of a medical product authorized for use during an emergency, including by requiring products to be distributed through a state- or territorial-based system.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 6832 IN THE HOUSE OF REPRESENTATIVES February 25, 2022 Mr. Cloud (for himself, Mr. Webster of Florida , Mr. Biggs , Mrs. Miller of Illinois , Mr. Tiffany , and Mr. Donalds ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Financial Services , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID–19 pandemic.

1. Ensuring fairness for State contracts relating to supplies to combat COVID–19 pandemic (a) Treatment under Defense Production Act of 1950 Section 101 of the Defense Production Act of 1950 ( 50 U.S.C. 4511 ) is amended— (1) in subsection (a), by striking The President and inserting Except as provided by subsection (e), the President ; and (2) by adding at the end the following: (e) Exception for State contracts relating to COVID–19 pandemic The President may not exercise the authority provided by subsection (a) on or after the date of the enactment of this subsection to prioritize the performance of contracts or orders of the Federal Government relating to the purchase of supplies to combat the COVID–19 pandemic over the performance of contracts or orders of the government of a State or territory or possession of the United States relating to the purchase of such supplies. . (b) Treatment under Federal Food, Drug, and Cosmetic Act Section 564(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3(j) ) is amended by adding at the end the following: (5) Nothing in this section or any other provision of law shall be construed to authorize the Secretary to ration a drug authorized for use under this section, limit or restrict access to such a drug, or otherwise control the quantity of such a drug made available for or distributed to any State or territory, including by imposing any limitation on distribution of such a drug to governmental entities, such as requiring a State- and territorial-coordinated distribution system or similar distribution system. . (c) Use of COVID–19 relief funds To purchase supplies for States (1) In general Notwithstanding any other provision of law, a State or territory or possession of the United States may use funds described in paragraph (2) to purchase supplies to combat the COVID–19 pandemic that the State, territory, or possession was unable to purchase before the date of the enactment of this Act because of the invocation by the President of the authority to prioritize contracts and orders under section 101 of the Defense Production Act of 1950 ( 50 U.S.C. 4511 ). (2) Funds described Funds described in this paragraph are funds made available to a State or territory or possession of the United States pursuant to any of the following Acts and available for obligation as of the date of the enactment of this Act: (A) The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 ( Public Law 116–123 ; 134 Stat. 146). (B) The Families First Coronavirus Response Act ( Public Law 116–127 ; 134 Stat. 178). (C) The Coronavirus Aid, Relief, and Economic Security Act ( Public Law 116–136 ; 134 Stat. 281). (D) The Paycheck Protection Program and Health Care Enhancement Act ( Public Law 116–139 ; 134 Stat. 620). (E) The Consolidated Appropriations Act, 2021 ( Public Law 116–260 ). (F) The American Rescue Plan Act of 2021 ( Public Law 117–2 ). (G) Any other Act providing funding relating to the COVID–19 pandemic.